We also received FDA clearance to initiate clinical development of TSHA102 in pediatric patients in the US and have submitted a CTA to the MHRA for TSHA102 in pediatric patients with Rett syndrome which will expand our clinical evaluation to children with earlier stages of disease progression said Sean P Nolan  Chairman and Chief Executive Officer of Taysha